ct-l

CTL-06, a Fatty Acid Synthase (FASN) inhibitor with an IC50 of 3 μM, induces apoptosis, while CTL-12 impedes cell cycle progression in the Sub-G1/S phase and modulates apoptotic and anti-apoptotic markers by upregulating caspase-9 and Bax and downregulating Bcl-xL. Additionally, CTL-12 suppresses de novo lipogenesis, curtailing the metabolic needs of tumor cells, with utilization in breast and colorectal cancer studies [1].

CTL-12, a fatty acid synthase (FASN) inhibitor (IC50: 2.5 μM), induces apoptosis and disrupts the cell cycle at the Sub-G1/S phase. It upregulates caspase-9 and the apoptosis marker Bax, while downregulating the anti-apoptotic marker Bcl-xL. By inhibiting de novo lipogenesis, CTL-12 thwarts tumor cells' metabolic requirements and is frequently employed in breast and colorectal cancer studies [1].

Marizomib is a novel irreversible brain-permeable proteasome inhibitor that inhibits CT-L (β5), CT-T-laspase-like (C-L, β1), and trypsin-like (T-L, β2) 20S proteasomes with IC50s of 3.5, 28, and 430 nM.[3]

Erlotinib (NSC-718781) is an EGFR inhibitor (IC50: 2 nM). It is used for the treatment of non-small cell lung cancer.

ESI-05 (NSC-116966) is a specific EPAC2 (exchange protein directly activated by cAMP 2) antagonist (IC50: 0.4 μM). ESI-05 inhibits cAMP-mediated activation of EPAC2, as well as EAPC2, mediated Rap1 activation.

CTL26 is an effective, orally active α-glucosidase inhibitor, with an IC50 value of 2.81 µM, demonstrating antidiabetic properties.

B7/CD28 interaction inhibitor 1 (CTLA-4 inhibitor) is a potent CTLA-4 inhibitor.

Boc-Tle-OH is an amino acid derivative and has a wide range of applications in life science related research.

(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3,3-dimethylbutanoic acid is a useful organic compound for research related to life sciences. The catalog number is T66690 and the CAS number is 132684-60-7.

Tremelimumab is a cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blocking antibody.Tremelimumab is often used in combination with Durvalumab for the treatment of solid cancers such as hepatocellular carcinoma and lung cancer.

Tisagenlecleucel (CTL019), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, selectively targets and eradicates CD19-expressing B cells, and is utilized in the study of refractory aggressive diffuse large B-cell lymphoma [1] [2].

QPCTL-IN-1 (compound 9) serves as a potent inhibitor of the glutaminyl-peptide cyclotransferase-like protein (QPCTL). It is employed in cancer research [1].

Anti-CTLA-4/CD152 Antibody is a human-derived antibody expressed in CHO cells, targeting CTLA-4/CD152. It features a huIgG4SP heavy chain and a huκ light chain, with an estimated molecular weight (MW) of 145 kDa. For isotype control, refer to Human IgG1kappa, Isotype Control.

Anti-CTLA-8/IL-17a Antibody is a human-derived antibody expressed by CHO cells, targeting CTLA-8/IL-17a. It features a huIgG1 heavy chain and a huκ light chain, with an estimated molecular weight (MW) of 150 kDa. For isotype control, refer to HumanIgG1kappa, Isotype Control.

Volrustomig is a bi-engineered fragment crystallizable (Fc) domain, a monovalent bispecific IgG1 monoclonal antibody targeting the key immune checkpoint receptors PD-1 and CTLA-4. It boosts T-cell activation and antitumor immunity, making it a promising immunotherapy for various cancers. Molecular weight: 146.77 kDa.

BC-23 (NSC 45382) is a potent proteasome inhibitor with antitumor and antimicrobial activity, inhibiting the CT-L activity of the proteasome and used in the study of leukemias, lymphomas, gliomas, breast cancer, and small cell lung cancer.

Oprozomib (PR-047) (ONX 0912) , an inhibitor for CT-L activity of 20S proteasome β5(IC50=36 nM)/LMP7(IC50=82 nM), is orally bioavailable. Oprozomib also has potential antineoplastic activity.

PI-1840(IC50 = 27 nM)is a reversible and selective chymotrypsin-like (CT-L) inhibitor, with little proteasome proteolytic effects on trypsin-like (T-L) and postglutamyl-peptide-hydrolysis-like (PGPH-L).

Enzyme-IN-1 (compound 1), a peptide-based inhibitor of N-terminal nucleophile (Ntn) hydrolases, specifically targets and inhibits the chymotrypsin-like activity (CT-L) of the 20S proteasome. This compound may possess potential anti-inflammatory properties [1].

BT317 is a brain-penetrant dual inhibitor of mitochondrial LonP1 protease and CT-L proteasome activity. BT317 increases ROS levels, induces apoptosis in astrocytoma cells, and exhibits antitumor effects.